The role of clinical pharmacology in improving the prevention and trea
tment of malaria is reviewed. A series of general and specific issues
is discussed, concentrating on risk-benefit and cost-effectiveness. Th
e techniques of clinical pharmacokinetics play an important role in th
e optimal use of drugs and this is illustrated by studies on quinine a
nd proguanil. In discussing amodiaquine toxicity, the role of the phar
macologist and the chemist in designing out drug toxicity lends hope f
or producing a new generation of antimalarial drugs.